Mr. Hawkins is currently the Chairman and CEO of LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company, where he served as Chairman, President, and Chief Executive Officer.
In addition, Mr. Hawkins was a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. In addition to his role as Chairman of the Board for LabNow Inc., Mr. Hawkins also currently serves on the Board of Directors of Synarc, Inc. and SciClone Pharmaceuticals Inc.
Paul W. Hawran joined Cytori Therapeutics as Director in February 2005. Mr. Hawran has served as Chief Financial Officer of Sequenom, Inc., since April 2007. He previously served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. starting in January 2001. Prior to that, he served as Senior Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. for five years and Vice President and Chief Financial Officer for three years prior. Mr. Hawran has also held executive management positions at SmithKline Beecham (now Glaxo SmithKline), most recently as Vice President and Treasurer. Prior to joining SmithKline in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John's University and an M.S. in taxation from Seton Hall University. He is a certified public accountant and a member of the American Institute of Certified Public Accountant.
Ronald D. Henriksen joined Cytori Therapeutics as Director in October 2002 and was previously a Board member of its predecessor, StemSource, Inc. Mr. Henriksen has more than 30 years of experience in healthcare, pharmaceutical, biotechnology and consulting and venture capital industries. He currently serves as Chief Investment Officer of Twilight Ventures, LLC, and Chairman of the Board of Semafore Pharmaceuticals and EndGenitor Technologies, of which he is also Founder and President. For more than 20 years, Mr. Henriksen held executive positions with Eli Lilly, where he served as Managing Director for Brazil, Mexico and Central America, and negotiated international contracts through Lilly Business Development. Additional Board Directorships include board member positions of QLT, Inc., Canada's second largest biopharmaceutical company, PreMD, Inc and BioStorage Technologies. Mr. Henriksen received his B.S. in Industrial Administration from Iowa State University and an M.B.A. with distinction from Harvard Business School. He also served as an officer for four years in the U.S. Navy.
E. Carmack Holmes, M.D., joined Cytori Therapeutics as Director in August 2003. Dr. Holmes serves as the Surgeon-in-Chief of the University of California Los Angeles (UCLA) Medical Center and holds the position of William P. Longmire, Jr. Professor and Chairman, Department of Surgery, UCLA School of Medicine. He joined UCLA in 1973 and has held professorial positions in the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years. He served as Vice-Chairman for five years prior to holding the positions of Chairman and Surgeon-in-Chief for the past ten years. Dr. Holmes is the recipient of numerous awards and grants and professional memberships include the American Surgical Association, the American College of Surgeons and the Association for Academic Surgeons. He has authored 250 medical publications throughout his career and has been an internationally invited lecturer for over 25 years. His surgical training was conducted at The Johns Hopkins University and the National Cancer Institute at the National Institutes of Health (NIH). Dr. Holmes graduated from Duke University and holds an M.D. from the University of North Carolina Medical School.
David Rickey has served as a Director of MacroPore Biosurgery since November 1999. From 1996 to March 2005 Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation, which provides high-performance, high-bandwidth silicon solutions for optical networks. Mr. Rickey also served as a Director and Chairman of the board of Applied Micro Circuits Corporation and currently serves on the board of AMI Semiconductor, Inc. and Netlist. Mr. Rickey holds two BS degrees from Marietta College and Columbia University and an MS from Stanford University.
Stock transaction information provided by EDGAR Online. Cytori Therapeutics makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Contact the Board
You can contact Cytori Therapeutics's Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
Corporate Secretary
Cytori Therapeutics 3020 Callan Road San Diego, CA 92121
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Cytori Therapeutics board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
Product complaints
Product inquiries
New product suggestions
Resumes and other forms of job inquiries
Surveys
Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
= Chair 
= Member
Director 
Interim Chairman of the Board 
Director